CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (11)

Name (Synonyms) Correlation
drug948 Recombinant Human Interferon α2b Spray Wiki 0.71
drug802 Other drugs Wiki 0.71
drug80 Arbidol Hydrochloride Granules Wiki 0.71
drug1148 Therapeutic Anticoagulation Wiki 0.71
drug188 Bromhexine Hydrochloride Tablets Wiki 0.71
drug1128 Telehealth monitoring Wiki 0.71
drug752 Nitazoxanide Wiki 0.41
drug612 Ivermectin Wiki 0.29
drug262 Chloroquine Wiki 0.27
drug431 Favipiravir Wiki 0.22
drug850 Placebo Wiki 0.06

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D020141 Hemostatic Disorders NIH 0.35
D001778 Blood Coagulation Disorders NIH 0.35
D011014 Pneumonia NIH 0.05
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0001928 Abnormality of coagulation HPO 0.35
HP:0002090 Pneumonia HPO 0.05

There are 2 clinical trials

Clinical Trials

1 The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19

COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.

NCT04345419 COVID Drug: Chloroquine Drug: Favipiravir Drug: Nitazoxanide Drug: Ivermectin Drug: Niclosamide Drug: Other drugs

Primary Outcomes

Description: the estimated number of patients with decreased viral load

Measure: Number of patients with decreased viral load

Time: 6 months

2 Niclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)

This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).

NCT04399356 COVID (SARS-CoV-2) Drug: Niclosamide Drug: Placebo Other: Telehealth monitoring

Primary Outcomes

Description: Oropharangeal swab

Measure: Change in respiratory viral clearance (by PCR)

Time: Day 3 and 10

Secondary Outcomes

Description: Fecal swab

Measure: Fecal viral clearance (by PCR)

Time: Day 14

Description: Oropharngeal swab

Measure: Reduction (change) in viral shedding (by PCR)

Time: Days 1,3,7,10,14

No related HPO nodes (Using clinical trials)